Pharmaceutical Glass Packaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The pharmaceutical glass packaging market size was valued at USD 31.01 billion in 2025 and is estimated to grow from USD 32.85 billion in 2026 to reach USD 41.74 billion by 2031, at a CAGR of 4.91% during the forecast period (2026-2031). This report is Segmented by Product (Bottles, Vials, Ampoules, and More), Glass Type (Type I Borosilicate, Type II Treated Soda-Lime, and More), Drug Formulation (Injectables, Oral Liquids, Ophthalmic/Nasal, and More), End-User (Pharma Innovator Companies, Generic and CMOs, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Pharmaceutical Glass Packaging Market Trends and Insights

Expansion Of Biologics And Injectable Drugs Pipeline

The pharmaceutical glass packaging market is riding a surge of late-stage biologics, with 2,517 candidates in Phase II and III by 2025. More than two-thirds require parenteral delivery in low-extractable Type I containers to safeguard protein structure during a 24-month shelf life. Annual launch volumes for monoclonal antibody therapies can top 150 million vials or prefillable syringes, establishing a multi-year base load that smooths capacity utilization. Cell and gene therapies now account for almost one-fifth of the pipeline and require pre-sterilized vials with extractables below 1 ppm, raising the technical barrier for competing materials. Investment in RTU filling lines by both West Pharmaceutical Services and Stevanato Group underpins this shift toward high-purity formats.

Mounting Vaccine Fill-Finish Capacity Post-COVID

Global fill-finish throughput expanded 47 % between 2020-2024, adding 8.3 billion annual doses, largely in India, Indonesia, South Africa, and Brazil. Those lines were standardized on 2- and 5-milliliter Type I vials compatible with mRNA and viral-vector vaccines. Serum Institute of India intends to retain 80 % of its COVID-era output for routine immunizations, locking in roughly 1.2 billion vials per year. Twenty-three low- and middle-income countries have now established or expanded domestic vaccine lines, and 19 of them specify Type I glass, reflecting regulatory familiarity.

Rapid Adoption Of COP/COC Polymer Syringes

Polymer syringes reached 18% market share in 2025 as drug firms moved to eliminate silicon oil and tungsten leachables from glass barrels. Terumo’s March 2025 acquisition of Recipharm’s assets will triple polymer syringe capacity to 600 million units by 2027, intensifying competitive pressure on glass producers. Device designers also cite a 25% gain in dimensional precision, enabling higher-speed filling without additional vision checks, thereby lowering the total cost of ownership for high-throughput biologics lines. Regulatory acceptance is expanding after the FDA acknowledged COP and COC as suitable parenteral container materials in its 2024 guidance on container-closure systems.

Other drivers and restraints analyzed in the detailed report include:

• Shift To Ready-To-Use Vials And Syringes
• Rising Demand for High-Value Borosilicate Type I Glass
• Volatile Soda-Ash and Energy Prices Inflating Glass Cost

Segment Analysis

Vials held a 40.53% share of the pharmaceutical glass packaging market in 2025, reflecting their entrenched position in vaccine fill-finish, lyophilized biologics, and multi-dose injectable applications, where established filling lines and regulatory familiarity give the format an edge. Cartridges and prefillable syringes are projected to grow at a 5.93% CAGR from 2026-2031, driven by patient-centric delivery for chronic diseases and the drug industry’s pivot toward devices that improve adherence and reduce hospital visits. Bottles, used for oral liquids and ophthalmic preparations, register modest gains as generic producers in India and China expand pediatric suspension portfolios, while ampoules slip as single-use convenience is outweighed by higher breakage during automated filling.

The swing from vials to prefillable syringes accelerates in biologics, where Stevanato Group’s EZ-fill nests and Gerresheimer’s Gx RTF syringes bypass secondary packaging and cold-chain complexity. Nipro’s October 2024 partnership with Corning to distribute Velocity Vial, which reduces particulate levels by up to 96%, highlights the push to sustain vial relevance even as syringe adoption climbs. Cartridges dominate insulin and GLP-1 devices, leveraging multi-dose precision and West Pharmaceutical Services’ Westar ready-to-use components as the de-facto standard. Ampoules still serve emergency medicine and veterinary markets that prize hermetic sealing, and the “other product” niche, dual-chamber vials and blow-fill-seal, expands at a 4.2 % CAGR as CDMOs pursue proprietary packages that deter biosimilar substitution.

Type I borosilicate glass captured 54.56% of the pharmaceutical glass packaging market share in 2025 and is forecast to expand at a 5.67% CAGR through 2031 as biologics, vaccines, and high-pH injectables standardize on its chemical durability. Type II treated soda-lime, upgraded by sulfur dioxide surface treatment, serves price-sensitive generics but loses ground as global filings increasingly default to Type I to avoid costly revalidation. Type III soda-lime, limited to non-parenteral formats such as oral liquids and topicals, grows only 3.8% CAGR as lightweight plastics erode share in pediatric suspensions.

Plasma ion-exchange research from the University of Padua shows that modified Type I surfaces cut protein adsorption 68 % and sodium leaching by 82 %, enabling concentrations above 150 mg/ml without viscosity reducers, a breakthrough attracting antibody-drug conjugate developers. Schott’s USD 450 million investment program, announced in 2025 and spanning Germany and India, aims to reduce 12-18-month lead times for custom Type I molds. Type II glass clings to markets constrained by budgetary pressures, notably sub-Saharan Africa and South Asia, yet its 35-50% price discount fails to entice innovators locked into Type I by stringent extractables tests. “Other glass” lines, amber formats for light-sensitive drugs and low-friction coatings like Velocity Vial, push a 6.1 % CAGR as firms chase functional differentiation, and ISO 15378 traceability rules further cement Type I dominance.

Complete Report Scope:

• By Product
  • Bottles
  • Vials
  • Ampoules
  • Cartridges and Prefillable Syringes
  • Other Product
• By Glass Type
  • Type I Borosilicate
  • Type II Treated Soda-Lime
  • Type III Soda-Lime
  • Other Glass Type
• By Drug Formulation
  • Injectables
  • Oral Liquids
  • Ophthalmic / Nasal
  • Topical
• By End-User
  • Pharma Innovator Companies
  • Generic and CMOs
  • Biotech Firms
  • Compounding Pharmacies
  • Veterinary Pharma
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia and New Zealand
    • Rest of Asia-Pacific
  • Middle East and Africa
    • Middle East
    • Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

Asia-Pacific captured 34.96 % in 2025, reflecting China’s 9 billion-unit output and India’s emergence as a global fill-finish hub. Japanese firms focus on high-precision syringes and surface-engineered vials exported worldwide. Regulatory alignment with ICH Q3D promotes standardization around Type I glass, driving a 5.2% regional CAGR.

Asia-Pacific is poised for a 5.88% CAGR, driven by local vaccine mandates and the African Vaccine Manufacturing Initiative. Furnace builds in South Africa, Kenya, and Nigeria offset logistical hurdles associated with raw-material imports. Capacity still lags demand, so multinationals are entering joint ventures to secure early market share.

Europe and North America together accounted for 42.1% of 2025 demand, driving trading volume growth and margin accretion through RTU conversions and AI inspection rollouts. Recycling targets under the EU Green Deal raise cullet recovery rates to 78% in leading member states, reinforcing glass’s sustainability narrative. South America advances at a 4.7% CAGR, led by Brazil’s biosimilar push and government procurement rules that localize packaging.

List of Companies Covered in this Report:

• Gerresheimer AG
• Schott AG
• SGD Pharma
• Stevanato Group
• Corning Inc.
• Nipro Corporation
• West Pharmaceutical Services Inc.
• Bormioli Pharma S.p.A.
• Owens-Illinois Inc. (Ardagh Glass Pharma)
• Stoelzle Oberglas GmbH
• Beatson Clark Ltd.
• Shandong Medicinal Glass Co. Ltd.
• Arab Pharmaceutical Glass Co.
• Piramal Glass Private Ltd.
• Şişecam Group
• Baxter BioPharma Solutions LLC
• Kindeva Drug Delivery L.P.
• Origin Pharma Packaging Ltd.
• DWK Life Sciences GmbH
• GerroMed GmbH

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support